Arrested Agonist Paradigm For Selective Radiosensitization of Prostate Cancer
Preprint
Abstract
As a prototypical nuclear hormone receptor, the androgen receptor (AR) signals via a sequential cascade triggered by binding to androgenic ligands such as testosterone and dihydrotestosterone (DHT). This cascade includes dimerization of the ligand-receptor complex, nuclear translocation, chromatin binding to response elements, recruitment of TOP2B and co-activator complexes, and induction of an effector transcriptional program. In prostate cancers, this AR signaling cascade is an essential driver of growth and survival, yet its activity confers potential vulnerabilities through transient TOP2B-mediated DNA double strand breaks. We investigated the ability of non-steroidal AR ligands to activate initial steps of the AR signaling cascade up to the point of AR- and TOP2B-mediated double strand breaks, with subsequent arrest of the signaling cascade to prevent induction of pro-growth/survival transcriptional programs in prostate cancer cells. We identified hydroxyflutamide (FLU) as such an androgen receptor arrested agonist; in androgen-deprived conditions, FLU induced AR nuclear translocation, chromatin binding, and TOP2B-mediated double strand breaks, but failed to induce AR target gene expression and prostate cancer cell growth. The FLU-mediated arrest in the signaling cascade could be attributed to the inability of FLU to allow association of AR with SMARCD2, a critical component of the BAF chromatin remodeling complex required for androgen induced AR co-activation. Interestingly, the FLU-induced, AR- and TOP2B-mediated double strand breaks could be used to selectively sensitize AR-positive prostate cancer cells to ionizing radiation in vitro and in vivo . These findings support a novel arrested agonist paradigm for selective radiosensitization of prostate cancer cells without inducing AR-mediated pro-growth and survival transcriptional programs.Keywords
This publication has 23 references indexed in Scilit:
- Targeting SWI/SNF ATPases in enhancer-addicted prostate cancerNature, 2021
- A Structural Model of the Endogenous Human BAF Complex Informs Disease MechanismsCell, 2020
- Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator ComplexesMolecular Cell, 2020
- Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling ComplexesCell, 2018
- A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexesNature Communications, 2018
- Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory FactorCell Reports, 2013
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangementsNature Genetics, 2010
- Oxidative DNA Damage Induced by Equine Estrogen Metabolites: Role of Estrogen Receptor αChemical Research in Toxicology, 2002
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990